REVIEW

Long term motor complications of levodopa: clinical features, mechanisms, and management strategies

B R Thanvi¹, T C N Lo²

¹ Department of Integrated Medicine, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK
² Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK

Correspondence to:
Correspondence to:
Dr B R Thanvi
Department of Integrated Medicine, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Infirmary Squire, Leicester LE1 5WW, UK; bthanvi{at}hotmail.com

Levodopa is the most effective symptomatic treatment of Parkinson’s disease. However, after an initial period of dramatic benefit, several limitations become apparent including, "dopa resistant" motor symptoms (postural abnormalities, freezing episodes, speech impairment), "dopa resistant" non-motor signs (autonomic dysfunction, mood and cognitive impairment, etc), and/or drug related side effects (especially psychosis, motor fluctuations, and dyskinesias). Motor complications include fluctuations, dyskinesias, and dystonias. They can be very disabling and difficult to treat. Therefore, strategies should ideally be developed to prevent them. Though mechanisms underlying motor complications are only partially understood, recent work has revealed the importance of pulsatile stimulation of postsynaptic dopamine receptors and the disease severity. As a result of intermittent stimulation there occurs a cascade of changes in cell signalling leading to upregulation of the N-methyl-D-aspartate subtype of gamma-aminobutryric acid-ergic neurones. Modified preparations of levodopa (controlled release preparations, liquid levodopa), catecholamine-o-methyltransferase inhibitors, dopamine agonists, amantidine, and various neurosurgical approaches have been used in the prevention and/or treatment of motor complications. Current management of motor complications is less than satisfactory. With better understanding of the pathogenetic mechanisms, it is hoped that future therapeutic strategies will provide a safer and targeted treatment.

Abbreviations: AADC, aromatic amino acid decarboxylase; COMT, catecholamine-o-methyltransferase; GABA, gamma-aminobutryric acid; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NMDA, N-methyl-D-aspartate

Keywords: Parkinson’s disease; levodopa; dyskinesia

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Pereira, E. A C, Aziz, T. Z (2006). Surgical insights into Parkinson's disease.. JRSM 99: 238-244 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Parkinson' disease - multidisciplinary team

Sunku H Guptha

Postgrad Med J Online, 31 Aug 2004 [Full text]